 The purpose of this study is to show safety and tolerability to our mesenchymal stromal cells MSCs product which will be autologous in nature, expanded using a non-xenogeneic, human component expansion media pooled human platelet lysate and delivered fresh. Subsequently, the investigators intend to test whether infusion of MSCs immediately after islet autograft can reduce onset of diabetes and improve glycemic control after total pancreatectomy and islet autotransplantation. 